D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

Benzinga · 11/03/2025 16:23
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.